Life sciences group Thermo Fisher agrees to acquire PE-owned drug trial software maker Clario for $9.4B in an all-cash deal expected to close by mid-2026 (Oliver Barnes/Financial Times)
PositiveArtificial Intelligence

Thermo Fisher has announced its acquisition of Clario, a drug trial software maker, for $9.4 billion in an all-cash deal expected to finalize by mid-2026. This acquisition is significant as it enhances Thermo Fisher's capabilities in the life sciences sector, allowing them to offer more comprehensive solutions in drug development and clinical trials. The move reflects the growing importance of technology in healthcare and could lead to improved efficiencies in drug testing processes.
— Curated by the World Pulse Now AI Editorial System





